Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treprostinil for Untreated Symptomatic PAH Trial: A 12-Week Multicenter Randomized Double-Blind Placebo-Controlled Trial of the Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension

NCT00494533 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.

NCT NCT00494533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00494533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treprostinil for Untreated Symptomatic PAH Trial: A 12-Week Multicenter Randomized Double-Blind Placebo-Controlled Trial of the Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension
Lead sponsor
United Therapeutics
Phase
Phase 4
Overall status
Terminated
Start date
March 31, 2005
Completion date
October 31, 2005
Enrollment
45 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension